Skip to main content

Syndax Pharmaceuticals, Inc.

corporate_fare Company Profile

Syndax Pharmaceuticals, Inc.

SNDX·NASDAQ·Life Sciences·CIK 0001395937

Our Company is a commercial-stage biopharmaceutical company focused on innovative cancer therapies. The company currently markets two FDA-approved medicines: Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr). Revuforj, a menin inhibitor, received its first U.S. Food and Drug Administration (FDA) approval in November 2024 for treating relapsed or refractory (R/R) acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients aged one year and older. In October 2025, Revuforj gained a second FDA approval for R/R acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 mutation (NPM1m) in adult and pediatric patients aged one year and older lacking satisfactory alternative treatment options. The company is also studying revumenib in combination with standard-of-care agents for NPM1m AML and KMT2A-rearranged (KMT2Ar) acute leukemia, including in newly diagnosed patients, and exploring its use in myelofibrosis (MF). Niktimvo, a colony stimulating factor-1 receptor (CSF-1R) blocking antibody, was FDA-approved in August 2024 for chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg. Axatilimab is also being developed for newly diagnosed cGVHD patients in combination with standard of care therapies, and for idiopathic pulmonary fibrosis (IPF). The company holds global rights to both revumenib and axatilimab. It leads the commercialization and development of revumenib and collaborates with Incyte on the commercialization and development of axatilimab.

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 16 items for SNDX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-02, rated 7/10. Across its 16 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for SNDX spans 10-Q, 8-K, DEFA14A, DEF 14A.

Recent high-impact activity:

  • Syndax 10-Q: Q3 Revenue $83.3M, Net Loss Narrows to $49.4M, $551M Cash
  • Syndax Q3 Revenue Jumps 82% to $83.3M; CFO Goldan Retires, Ondrey Named
  • Syndax Q2 Revenue Surges 92% to $72.8M, Loss Narrows; Pipeline Expands with Two New Assets
  • Syndax Q2 Revenue Jumps 92% to $73M, Loss Narrows; Pipeline Catalysts Loom
  • Syndax Adds Two Pipeline Assets and Lays Out a Catalyst-Rich Roadmap

Short Interest & Short Volume

6.41 days to cover

FINRA reported short interest of 18,920,163 shares in SNDX as of the October 30, 2026 settlement, a 5.1% increase from the prior period — about 6.4 days to cover at its recent average daily volume. On November 20, 2026, 31.9% of SNDX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)18,920,163 shares as of October 30, 2026
Change vs prior period▲ 5.1%
Days to cover6.41 at avg daily volume of 2,951,578
Daily short volume (FINRA facilities)31.9% of 791,753 shares on November 20, 2026
5-day average short volume38.5%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for SNDX, detected from its recent SEC filings · based on capital-structure filings through 2026-06-10.

$250 Million Convertible Notes Issued · $243 Million Net Proceeds

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with S →
$8.72
52-week range · as of 2026-11-02 $8.72 – $25.59
Market cap
$785.05M
Volume
2.2M (0.6× avg)
3-mo avg 3.7M
Live data · 2026-11-22 12:40 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed SNDX - Latest Insights

SNDX
Nov 02, 2026, 4:04 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $12.91
Real-time Price: $8.72 info
Change: -$4.19 (-32%) info
Market Cap: $785.046M info
SNDX
Nov 02, 2026, 4:02 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $12.90
Real-time Price: $8.72 info
Change: -$4.18 (-32%) info
Market Cap: $785.046M info
SNDX
Aug 04, 2026, 4:04 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $17.76
Real-time Price: $8.72 info
Change: -$9.04 (-51%) info
Market Cap: $785.046M info
SNDX
Aug 04, 2026, 4:02 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $17.98
Real-time Price: $8.72 info
Change: -$9.26 (-52%) info
Market Cap: $785.046M info
SNDX
Jul 14, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $22.89
Real-time Price: $8.72 info
Change: -$14.17 (-62%) info
Market Cap: $785.046M info
SNDX
Jun 12, 2026, 3:13 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $17.91
Real-time Price: $8.72 info
Change: -$9.19 (-51%) info
Market Cap: $785.046M info
SNDX
Jun 10, 2026, 5:04 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $17.58
Real-time Price: $8.72 info
Change: -$8.86 (-50%) info
Market Cap: $785.046M info
SNDX
Jun 10, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $17.58
Real-time Price: $8.72 info
Change: -$8.86 (-50%) info
Market Cap: $785.046M info
SNDX
Jun 04, 2026, 8:36 AM EDT
Filing Type: DEFA14A
Importance Score:
8
Price at Filing: $16.80
Real-time Price: $8.72 info
Change: -$8.08 (-48%) info
Market Cap: $785.046M info
SNDX
Jun 04, 2026, 7:16 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $18.43
Real-time Price: $8.72 info
Change: -$9.71 (-53%) info
Market Cap: $785.046M info
SNDX
Apr 30, 2026, 5:20 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $20.40
Real-time Price: $8.72 info
Change: -$11.68 (-57%) info
Market Cap: $785.046M info
SNDX
Apr 30, 2026, 4:02 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $20.57
Real-time Price: $8.72 info
Change: -$11.85 (-58%) info
Market Cap: $785.046M info
SNDX
Feb 26, 2026, 4:04 PM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $20.02
Real-time Price: $8.72 info
Change: -$11.30 (-56%) info
Market Cap: $785.046M info
SNDX
Feb 26, 2026, 4:02 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $20.02
Real-time Price: $8.72 info
Change: -$11.30 (-56%) info
Market Cap: $785.046M info
SNDX
Feb 06, 2026, 5:54 PM EST
Filing Type: 4
Importance Score:
7
Price at Filing: $20.80
Real-time Price: $8.72 info
Change: -$12.08 (-58%) info
Market Cap: $785.046M info
SNDX
Jan 12, 2026, 4:36 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $20.72
Real-time Price: $8.72 info
Change: -$12.00 (-58%) info
Market Cap: $785.046M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets